Literature DB >> 33606065

Development and validation of a PD-L1/PD-1/CD8 axis-based classifier to predict cancer survival of upper tract urothelial carcinoma after radical nephroureterectomy.

Junyu Chen1,2, Wenlong Zhong1,2, Meng Yang3, Weibin Hou1,2, Xiaofei Wang1,2, Kun Xia1,2, Hao Yu1,2, Meihua Yang1,2, Bingkun Zhou1,2, Bo Wang4,5, Jian Huang6,7, Tianxin Lin8,9,10.   

Abstract

The expression status of programmed cell death-ligand 1/programmed cell death 1 (PD-L1/PD-1) and the infiltration of CD8+ T cells in tumor tissues are considered to be related to immunotherapy efficacy and patient prognosis. The purpose of this study is to clarify the prognostic value of the PD-L1/PD-1/CD8 axis, and to develop and validate a comprehensive scoring system based on multiple immune variables to predict cancer survival of upper tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU). The immunohistochemical method was used to detect the expression of PD-L1, PD-1, and CD8 in cancer tissues of UTUC patients after RNU. Then, an immunoscore was constructed using the least absolute shrinkage and selection operator (LASSO) Cox regression model in the training cohort (n = 120), and it was verified in the validation cohort (n = 54). We found that infiltration of PD-L1+ immune cells (ICs), stromal PD-1+ tumor-infiltrating lymphocytes (TILs), and intratumoral CD8+ TILs was associated with poor overall survival (OS). The immunoscore based on the three immune variables further divided the patients into low- and high-risk groups, and there was a significant difference in the survival rate. A nomogram was constructed by combining tumor-node-metastasis (TNM) stage and immunoscore, and the area under the curve of the receiver-operating characteristic (ROC) (0.78) for predicting 5-year mortality was better than that of the TNM stage (0.70) and immunoscore (0.76). Our results show that the PD-L1/PD-1/CD8 axis-based classifier have potential clinical application to predict cancer survival of UTUC patients after RNU.

Entities:  

Keywords:  CD8; Overall survival; PD-L1; Prognostic classifier; Upper tract urothelial carcinoma

Year:  2021        PMID: 33606065     DOI: 10.1007/s00262-020-02827-x

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  27 in total

Review 1.  European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2020 Update.

Authors:  Morgan Rouprêt; Marko Babjuk; Maximilian Burger; Otakar Capoun; Daniel Cohen; Eva M Compérat; Nigel C Cowan; Jose L Dominguez-Escrig; Paolo Gontero; A Hugh Mostafid; Joan Palou; Benoit Peyronnet; Thomas Seisen; Viktor Soukup; Richard J Sylvester; Bas W G van Rhijn; Richard Zigeuner; Shahrokh F Shariat
Journal:  Eur Urol       Date:  2020-06-24       Impact factor: 20.096

Review 2.  Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature.

Authors:  Giovanni Lughezzani; Maximilian Burger; Vitaly Margulis; Surena F Matin; Giacomo Novara; Morgan Roupret; Shahrokh F Shariat; Christopher G Wood; Richard Zigeuner
Journal:  Eur Urol       Date:  2012-02-23       Impact factor: 20.096

Review 3.  A systematic review and meta-analysis of adjuvant and neoadjuvant chemotherapy for upper tract urothelial carcinoma.

Authors:  Jeffrey J Leow; William Martin-Doyle; André P Fay; Toni K Choueiri; Steven L Chang; Joaquim Bellmunt
Journal:  Eur Urol       Date:  2014-03-16       Impact factor: 20.096

4.  Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma.

Authors:  Thomas Seisen; Ross E Krasnow; Joaquim Bellmunt; Morgan Rouprêt; Jeffrey J Leow; Stuart R Lipsitz; Malte W Vetterlein; Mark A Preston; Nawar Hanna; Adam S Kibel; Maxine Sun; Toni K Choueiri; Quoc-Dien Trinh; Steven L Chang
Journal:  J Clin Oncol       Date:  2017-01-03       Impact factor: 44.544

Review 5.  Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel.

Authors:  Thomas Seisen; Benoit Peyronnet; Jose Luis Dominguez-Escrig; Harman M Bruins; Cathy Yuhong Yuan; Marko Babjuk; Andreas Böhle; Maximilian Burger; Eva M Compérat; Nigel C Cowan; Eero Kaasinen; Joan Palou; Bas W G van Rhijn; Richard J Sylvester; Richard Zigeuner; Shahrokh F Shariat; Morgan Rouprêt
Journal:  Eur Urol       Date:  2016-07-28       Impact factor: 20.096

6.  Prevalence and factors associated with baseline chronic kidney disease in China: a 10-year study of 785 upper urinary tract urothelial carcinoma patients.

Authors:  Gengyan Xiong; Xiaopeng Chen; Xuesong Li; Dong Fang; Luxia Zhang; Li Yang; Lei Zhang; Lin Yao; Zhisong He; Liqun Zhou
Journal:  J Formos Med Assoc       Date:  2013-05-15       Impact factor: 3.282

7.  Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration.

Authors:  Vitaly Margulis; Shahrokh F Shariat; Surena F Matin; Ashish M Kamat; Richard Zigeuner; Eiji Kikuchi; Yair Lotan; Alon Weizer; Jay D Raman; Christopher G Wood
Journal:  Cancer       Date:  2009-03-15       Impact factor: 6.860

8.  Nomogram predicting renal insufficiency after nephroureterectomy for upper tract urothelial carcinoma in the Chinese population: exclusion of ineligible candidates for adjuvant chemotherapy.

Authors:  Dong Fang; Qifu Zhang; Xuesong Li; Cheng Qian; Gengyan Xiong; Lei Zhang; Xiaopeng Chen; Xiaoyu Zhang; Wei Yu; Zhisong He; Liqun Zhou
Journal:  Biomed Res Int       Date:  2014-08-10       Impact factor: 3.411

9.  Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.

Authors:  Manish R Patel; John Ellerton; Jeffrey R Infante; Manish Agrawal; Michael Gordon; Raid Aljumaily; Carolyn D Britten; Luc Dirix; Keun-Wook Lee; Mathew Taylor; Patrick Schöffski; Ding Wang; Alain Ravaud; Arnold B Gelb; Junyuan Xiong; Galit Rosen; James L Gulley; Andrea B Apolo
Journal:  Lancet Oncol       Date:  2017-12-05       Impact factor: 41.316

10.  High-Level Production of a Thermostable Mutant of Yarrowia lipolytica Lipase 2 in Pichia pastoris.

Authors:  Qinghua Zhou; Zhixin Su; Liangcheng Jiao; Yao Wang; Kaixin Yang; Wenjuan Li; Yunjun Yan
Journal:  Int J Mol Sci       Date:  2019-12-31       Impact factor: 5.923

View more
  2 in total

1.  Analyzing the characteristics of immune cell infiltration in lung adenocarcinoma via bioinformatics to predict the effect of immunotherapy.

Authors:  Yi Liao; Dingxiu He; Fuqiang Wen
Journal:  Immunogenetics       Date:  2021-07-24       Impact factor: 2.846

2.  A Systematic Review and Meta-Analysis of Prognostic Nomograms After UTUC Surgery.

Authors:  Maximilian Pallauf; Frederik König; David D'Andrea; Ekaterina Laukhtina; Hadi Mostafaei; Reza Sari Motlagh; Fahad Quhal; Abdulmajeed Aydh; Takafumi Yanagisawa; Tatsushi Kawada; Pawel Rajwa; Lukas Lusuardi; Francesco Soria; Pierre I Karakiewicz; Morgan Rouprêt; Michael Rink; Yair Lotan; Vitaly Margulis; Nirmish Singla; Evanguelos Xylinas; Shahrokh F Shariat; Benjamin Pradere
Journal:  Front Oncol       Date:  2022-07-01       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.